|| Checking for direct PDF access through Ovid
The risk of inducing lupus erythematosus is considered to be low or very low for most pharmacological agents, with the exception of some cardiovascular drugs (e.g. procainamide, hydralazine and quinidine). Concerns about drug-induced lupus are also emerging for newer biological modulators. Early diagnosis of drug-induced lupus is vital and requires symptom onset to be temporally related to drug initiation. Discontinuation of the causative agent is required in all cases of drug-induced lupus.